Panitumumab Injection: Advanced EGFR Targeting for mCRC – Global Supply by Ernest Oncology
In the precision-driven oncology landscape of 2026, Panitumumab remains a critical biologic therapy for patients with wild-type RAS metastatic colorectal cancer (mCRC). As the first fully human monoclonal antibody to target the epidermal growth factor receptor (EGFR), Panitumumab offers a high-affinity intervention that disrupts the signaling pathways essential for tumor cell survival and proliferation.
Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the international distribution of Panitumumab to the USA, UK, London, Abu Dhabi, Australia, and South Africa, providing validated cold-chain logistics and comprehensive regulatory documentation.
Technical Product Profile: Panitumumab 20mg/mL
Panitumumab is a sterile, preservative-free solution for intravenous (IV) infusion. Its "fully human" molecular structure is designed to reduce the risk of infusion-related reactions compared to chimeric antibodies.
Product Specifications
Active Ingredient: Panitumumab.
Concentration: 20 mg/mL (available in 100 mg/5 mL and 400 mg/20 mL single-dose vials).
Mechanism of Action: EGFR Inhibitor; binds to the EGFR on both normal and tumor cells, competitively inhibiting the binding of ligands.
Therapeutic Class: Recombinant Fully Human IgG2 Monoclonal Antibody.
Storage Requirements: Must be refrigerated at 2°C to 8°C. Do not freeze. Protect vials from direct light.
Primary Clinical Indications
Metastatic Colorectal Cancer (mCRC): Indicated as first-line treatment in combination with FOLFOX, or as monotherapy following disease progression in patients with wild-type RAS (both KRAS and NRAS) tumors.
RAS Testing Requirement: Efficacy is limited to patients with wild-type RAS; confirmed testing of exons 2, 3, and 4 is essential prior to initiation.
Why Source Panitumumab via Ernest Oncology?
Fully Human Precision: The fully human IgG2 structure minimizes immunogenicity, offering a favorable safety profile for long-term treatment cycles.
Proven Survival Outcomes: Significant improvements in progression-free survival (PFS) when integrated into modern chemotherapy regimens.
Validated Cold-Chain Shipping: Ernest Oncology utilizes IATA-compliant, temperature-monitored packaging to ensure Panitumumab maintains its biologic potency from India to London, Abu Dhabi, or Johannesburg.
Global Export Expertise: We provide all necessary documentation, including Certificates of Analysis (CoA) and origin certificates, ensuring smooth customs clearance in strictly regulated markets.
Global Distribution Reach: USA, UK, UAE, Australia, & South Africa
We specialize in high-efficiency pharmaceutical exports to major international healthcare hubs:
USA: Reliable procurement for specialized cancer centers and B2B pharmaceutical wholesalers.
UK & London: Supporting NHS Trusts and private oncology networks with consistent supply of critical biologics.
Abu Dhabi (UAE): Rapid delivery to the advanced clinical infrastructure and specialized hospitals of the Middle East.
Australia: Navigating TGA-compliant pathways to supply Australian oncology departments with authentic medications.
South Africa: Expanding access to high-tier targeted therapies across the Southern African medical sector.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
(Group of Ernest Pharmaceutical Pvt. Ltd.)
Partner with a verified leader for the bulk procurement of Panitumumab and specialized oncology medications.
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 Instant Chat:
